Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated e...
Q1 2026
May 11, 2026
FY 2025
Mar 30, 2026
Q4 2025
Q3 2025
Nov 10, 2025
Q2 2025
Aug 12, 2025